Magdalena Tyrpien

Magdalena Tyrpien is Senior Vice President and Head of Business Development at Forge Biologics. Previously, she was Director of Business Development at PTC Therapeutics, a global commercial stage small molecule and gene therapy biopharmaceutical company. Ms. Tyrpien was directly responsible for leading efforts around licensing and acquisition of assets and led a $268M company acquisition with a Phase III ready asset for patients with PKU. Her professional experience spans corporate business development, strategic planning, and investor relations in the biotechnology and venture capital industries across a range of therapeutic areas and stages of development. Prior to joining PTC, she spent 4+ years as Director of Corporate Strategy and Business Development at Abeona Therapeutics, a gene, and cell therapy company. In this role, she identified, acquired, licensed, and leveraged strategic assets, with a focus on cell and gene therapies for rare neurogenerative diseases. Ms. Tyrpien earned her B.A. from Montclair State University and an M.B.A. from the University of Liverpool (UK).